NeutroPhase is a dilute solution of hypochlorous acid, which is rapid-acting in saline with broad-spectrum antimicrobial properties. In September 2007, NovaBay received 510(K) approval from the US Food and Drug Administration to market NeutroPhase, also known as NVC-101.
Jack O’Reilly, NovaBay’s senior vice president of corporate and business development, said: “Our intellectual property continues to develop because of our scientists’s deepening understanding of NeutroPhase and our Aganocide anti-microbial compounds.”